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Abstract
Background: Longer life expectancy is associated with an increasing prevalence of kidney disease. Aging itself may
cause renal damage, but the spectrum of kidney disorders that affect elderly patients is diverse. Few studies, mostly
form US, Asia and West Europe found differences in the prevalence of some types of kidney diseases between
elderly and younger patients based on renal biopsy findings, with varied proportion between glomerulopathies and
arterionephrosclerosis as a dominant injury found. Here, for the first time in Eastern Europe we analyzed native
kidney biopsy findings and their relationship to clinical characteristics at the time of biopsy in elderly individuals
(aged ≥65) in comparison to younger adults (aged 18–64).
Methods: Biopsy and clinical data from 352 patients aged ≥65 were retrospectively identified, analyzed and
compared with a control group of 2214 individuals aged 18–64. All kidney biopsies studied were examined at
Medical University of Warsaw in years 2009–14.
Results: In elderly patients the leading indication for biopsy was nephrotic range proteinuria without hematuria
(34.2%) and the most prevalent pathologic diagnoses were: membranous glomerulonephritis (MGN) (18.2%), focal
segmental glomerulosclerosis (FSGS) (17.3%) amyloidosis (13.9%) and pauci immune glomerulonephritis (12.8%).
Hypertension and age-related lesions very rarely were found an exclusive or dominant finding in a kidney biopsy
(1.7%) and a cause of proteinuria (1.1%) in elderly individuals. There were 18.2% diabetics among elderly individuals,
and as much as 75% of them had no morphologic signs of diabetic kidney disease in the renal biopsy. Amyloidosis,
MGN, pauci immune GN, crescentic GN and light and/or heavy chain deposition disease (LCDD/HCDD) were more
frequent whereas IgA nephropathy (IgAN), lupus nephritis (LN) and thin basement membrane disease (TBMD) were
less common among elderly than in younger patients.
Conclusions: Proteinuria, a dominating manifestation in elderly patients subjected to kidney biopsy was most
commonly related to glomerulopathies. The relatively high prevalence of potentially curative kidney diseases in
elderly individuals implicates the importance of renal biopsy in these patients.
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Background
Elderly patients constitute the largest age group among
all individuals with chronic kidney disease (CKD). The
elderly are affected by the same types of kidney diseases
as younger individuals, but their clinical course and
morphological manifestation may be influenced by aging.
Senescence is associated with an eGFR decline by
approximately 0.8–1.7 ml/min per year, which limits
renal function reserve and makes an individual more
vulnerable to the influence of injurious factors, common
in the elderly population, such as hypertension, cardio-
vascular disease, diabetes, and drugs nephrotoxicity [1,
2]. The complexity of the background as well as clinical
and morphological manifestations of kidney injury im-
pede precise disease recognition, make it difficult to es-
tablish prognosis, and hinder proper treatment selection.
In a vast majority of cases renal biopsy is irreplaceable in
identifying treatable, reversible lesions, as well as in
defining both the activity and chronicity of kidney injury.
It has been documented that the percentage of patients
with the precise kidney disease recognition decreases
with age and most of patients aged ≥55 are labelled as
‘CKD of unknown origin’ or ‘nephroangiosclerosis’ [3].
Many nephrologists no longer consider older age as a
contraindication to immunosuppressive treatment,
which is in line with the growing number of kidney bi-
opsies performed in elderly patients [4].
Methods
Study design
This is a quantitative, descriptive and cross-sectional
study that included a group of 2566 adult patients with
kidney biopsies that were considered diagnostic (i.e.,
containing sufficient amount of renal cortex for light
microscopic and immunomorphological evaluation as
well as ultrastructural study whenever necessary for
establishing the diagnosis), and were processed and
interpreted over the period of 2009–2014 in the Nephro-
pathological Laboratory, Department of Transplantology,
Nephrology and Internal Medicine at Medical University
of Warsaw. Among patients studied we identified 352
elderly individuals (accepting an defining age of ≥65 [5])
as well as a control group of 2214 patients aged 18–64
years. We analyzed kidney-biopsy based diagnoses in
terms of their prevalence and clinicopathological asso-
ciations in both cohorts. The list of clinical data sub-
jected to analysis included patients’ gender, age, eGFR
(MDRD), a pre-biopsy follow-up duration, the presence
of diabetes, hypertension, and urinalysis results. The
clinical categories of renal disease at the time of biopsy
were defined as follows: nephrotic range proteinuria
(≥3.5 g/day) with or without hematuria, non-nephrotic
proteinuria (<3.5 g/day) with or without hematuria,
isolated hematuria.
To base our study on most credible and objective
measurements, all presumptive and interpretative data,
such as those relating to the acuteness/chronicity as well
as dynamics of kidney disease evolution, were excluded
from the analysis. As the definition of Acute Kidney
Injury (AKI) has been changing over the last several
years and we were not able to verify the historical data,
we didn’t include this clinical course characteristic in
our analysis.
Pathologic diagnoses
In all cases light microscopic (LM) evaluation and im-
munofluorescence (IFL) (for IgG, IgA, IgM, C3, C1q,
fibrinogen, kappa and lambda lights chains) were per-
formed. The diagnosis of immune-complex mediated
glomerulopathies, such as IgAN, MGN, LN, etc. was
based on the IFL and LM findings. In 44.8% of biopsies
an examination in electron microscopy was also done,
which was decided whenever the final diagnosis could
not have been made without it. Most commonly the
ultrastructural analysis was performed due to: 1) an un-
specific/incoherent LM and/or IFL findings; 2) a suspi-
cion of different nephropathies overlap (e.g., DKD
coexisting with immune-complex mediated glomerulo-
nephritis); 3) a discrepancy between clinical patients’
characteristics and morphological findings in LM and
IFL; and 4) a suspected paraproteinemia. The list of
morphological diagnoses is presented in Additional file
1: Table S1. We decided not to use the distinction be-
tween primary and secondary nephropathies assuming
that at least some cases considered primary at the time
of biopsy might have later changed their category once a
detailed diagnostic process was completed.
Statistical analyses
The statistical analysis was performed using SAS 9.4
software for Windows. Quantitative variables were
summarized by medians (ranges), because the parame-
ters did not follow a normal distribution and they were
compared using Wilcoxon Rank-Sum test. Qualitative
variables were compared using the χ2-test and Fisher’s
exact test, respectively to the sample size. A P-value of
<0.05 was considered statistically significant.
Results
Baseline characteristics are presented in Table 1. The
spectrum of renal biopsy diagnoses in elderly and youn-
ger patients is shown in Table 2. Three leading renal bi-
opsy diagnoses among elderly patients were MGN,
FSGS, and amyloidosis, whereas in younger individuals
IgAN, FSGS and MGN were most frequent ones. In
comparison to younger patients the elderly cohort was
characterized by higher prevalence of MGN, amyloid-
osis, pauci immune GN, crescentic GN, tubulointerstitial
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inflammation, and light chain/heavy chain deposition
disease (LCDD/HCDD) as well as lower prevalence of
IgAN, lupus nephritis (LN) and thin basement mem-
brane disease (TBMD). The pre-biopsy follow-up data
(Additional file 2: Table S2) have been used to define
patients’ age at the disease onset, and in the frequency
analysis of selected nephropathies. Figure 1a illustrates
the frequency of selected nephropathies at different age-
groups, whereas Fig. 1b demonstrates their frequencies
in relation to all nephropathies (renal biopsy based diag-
noses) occurring in a particular age group.
Clinical manifestation of kidney disease in elderly and
younger patients
A majority among elderly patients presented neph-
rotic range proteinuria (55.6%) in contrast to youn-
ger cohort in which non-nephrotic proteinuria
dominated (52.5%, P < 0.001) (Table 1). Among eld-
erly patients with nephrotic range proteinuria the
leading diagnoses were MGN (25%), amyloidosis
(20.2%) and FSGS (20.2%) in contrast to younger
cohort with this clinical syndrome, in which most
prevalent were FSGS (17.5%), MGN (16.9%) and
IgAN (16.8%). Among elderly patients, a majority of
those with nephrotic range proteinuria had no
hematuria, and this clinical presentation was most
commonly associated with amyloidosis (25.2%)
(Table 3).
Among elderly patients with non-nephrotic range pro-
teinuria the most common diagnoses were pauci im-
mune GN (21.6%), FSGS (17.2%) and IgAN (14.9%),
whereas in individuals aged 18–64 years with this clin-
ical syndrome IgAN (36.7%), FSGS (14.5%) and LN
(9.1%) were most prevalent ones (Table 4).
An isolated hematuria was seen in only 2.4% of
elderly patients studied, and was most commonly as-
sociated with nonspecific lesions best defined as
‘minor glomerular abnormalities’ (MGA). In younger
individuals an isolated hematuria was a presenting
symptom in only 3.4% of patients aged <65, and was
most commonly associated with IgA-N (23.6%), MGA
(18.1%), and TBMD (14.0%).
Table 1 Clinical characteristics at the time of biopsy by age
Elderly (aged ≥65) (n = 352) Younger (aged 18–64) (n = 2214) P
Male/female ratio 1:1 1.1/1
Age of disease onset median: 69 (range: 19–87) median: 37 (range: 1–64) <0.001

















Hematuria 159 (45.3%) 1359 (61.8%) <0.001
Nephrotic range proteinuria without hematuria 115 (34.2%) 453 (21.3%) <0.001
Non-nephrotic proteinuria with hematuria 76 (22.5%) 787 (37%)
Nephrotic range proteinuria with hematuria 73 (21.6%) 461 (21.6%)
Non-nephrotic proteinuria without hematuria 58 (17.2%) 328 (15.4%)
Isolated hematuria 8 (2.4%) 72 (3.4%)
eGFR mL/min/1.73 m2 median 39.3 (range 2.5–161.6) median 66.8 (range 2.7–252) <0.001
eGFR≥ 60 mL/min/1.73 m2 92 (26.1%) 1194 (53.9%) <0.001
eGFR 30–59 mL/min/1.73 m2 113 (32.1%) 548 (24.8%)
eGFR 15–29 mL/min/1.73 m2 73 (20.7%) 238 (10.8%)
eGFR < 15 mL/min/1.73 m2 74 (21%) 234 (10.5%)
Duration of symptoms < 3 months 165 (46.9%) 847 (38.3%) 0.002
Duration of symptoms ≥3 months 187 (53.1%) 1367 (61.7%)
Hypertension 287 (84.2%) 1398 (67.1%) <0.001
Diabetes 64 (18.5%) 160 (7.5%) <0.001
Steroid treatment before the biopsy 59 (17.5%) 491 (23.7%) 0.012
Other immunosuppressive treatment during pre-biopsy follow-up 16 (4.8%) 187 (9.0%) 0.008
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Renal biopsy diagnoses according to gender in the
elderly
Significant discrepancies between sexes were found in
the frequency of amyloidosis AA, more commonly seen
in females (10.8% vs. 3.4%, P = 0.011) and IgA-N, signifi-
cantly more frequently recognized in males (13.1% vs.
5.7%, P = 0.027).
Types of kidney disease in elderly diabetic individuals
Among patients aged ≥65 there were 64 (18.2%) individ-
uals with diabetes. The median time of diabetes duration
at the time of kidney biopsy was 7.16 years (range 0–24
years). In 11 (17%) of these patients kidney biopsy
revealed lesions consistent with pure DKD, in 4 (6%)
patients there were morphological features of DKD
coexisting with another type of kidney injury, and in 48
(75%) elderly diabetic patients there were no micro-
scopic features of DKD (Table 5). Among elderly
patients with diabetes and no DKD on kidney biopsy the
most prevalent type of kidney disease was pauci immune
GN (focal segmental and crescentic) associated with the
presence of ANCA.
Discussion
CKD, together with diabetes and cardiovascular disease
constitute three interrelated conditions of strong public
health relevance [6]. Reduced estimated eGFR is one of
the very important risk factors of cardiovascular disease
and death [7]. In US about 30–40% of adults aged ≥70,
and approximately 50% of those aged ≥80 have CKD [8,
9]. In Poland the prevalence of CKD in the elderly popu-
lation has been recently estimated at 29.4% [10]. In the
elderly CKD exerts stronger effect on the life expectancy
than in younger population [11]. Therefore, early detec-
tion of kidney disease, its type recognition, and the
implementation of targeted treatment should be
regarded as tools necessary to limit CKD complications
and to improve outcomes in cardiovascular diseases.
The complexity of renal injury among elderly individ-
uals obscures the clinical picture. Without a renal biopsy
the establishment of the proper diagnosis may be
impossible, or at least protracted [12–14].
There are no strict criteria qualifying patients to
kidney biopsy in any age group. As it has been defined
by Bomback et al., kidney biopsy should in general be
considered in any patient who presents at least 2 of the
Table 2 Renal biopsy diagnoses by age
Diagnosis Elderly (aged ≥65) (n = 352) Younger (aged 18–64) (n = 2214) P
MGN 64 (18.2%) 227 (10.3%) <0.001





























IgAN 33 (9.4%) 604 (27.3%) <0.001
Crescentic GN (types I,II,III) 31 (8.8%) 109 (4.9%) 0.005
MCD 22 (6.3%) 132 (6%) 0.809
DKD 16 (4.6%) 62 (2.9%) 0.100
Unclassified lesions 14 (4%) 92 (4.2%) 1.000
Tubulointerstitial nephritis 9 (2.6%) 34 (1.5%) 0.177
Membrano-proliferative GN 8 (2.3%) 67 (3%) 0.608
Arterionephrosclerosis (hypertensive nephropathy and aging nephropathy) 6 (1.7%) 18 (0.8%) 0.128
MGA 6 (1.7%) 79 (3.6%) 0.077
End-stage kidney 6 (1.7%) 39 (1.8%) 1.000
LN 5 (1.4%) 191 (8.6%) <0.001
LCDD/HCDD 4 (1.1%) 6 (0.3%) 0.037
Acute tubular injury/necrosis 4 (1.1%) 8 (0.4%) 0.070
Thrombotic microangiopathy 3 (0.9%) 39 (1.8%) 0.263
Normal kidney morphology 2 (0.6%) 29 (1.3%) 0.303
TBMD 1 (0.3%) 40 (1.8%) 0.036
The table encompasses only the diagnoses which were made in at least 1% of individuals in any of the two cohorts studied
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following findings: hematuria, proteinuria ≥1 g/day,
renal insufficiency, and/or positive serologies for
systemic diseases with known potential for kidney in-
volvement (e.g., hepatitis B or C virus infection, systemic
lupus erythematosus and ANCA seropositivity) [15]. As
it was emphasized, these indications apply to all age-
groups, including elderly (aged ≥65) and very elderly
(aged ≥80 years) patients. Several studies confirmed that
age is not a significant risk factor for biopsy-related
complications [13, 16, 17].
Although kidney biopsy offers the deepest insight into
the renal tissue injury, its morphological interpretation
may be problematic in the case of significant interfer-
ence by lesions related to aging, such as global glomeru-
losclerosis, arteriosclerosis, arteriolar hyalinization,
interstitial fibrosis and tubular atrophy. The additional
background injury may also be caused by long-lasting
hypertension and/or diabetes, as well as several environ-
mental and iatrogenic factors, which are relatively com-
mon in the elderly population.
In our elderly patients studied the most common clin-
ical manifestation of renal disease was nephrotic
syndrome (55.6%) with or without hematuria (21.6 and
34.2%, respectively) which was consistent with the
observations of others [14, 16, 18–21]. There are also
reports documenting AKI as a leading indication for na-
tive kidney biopsies in the elderly with nephrotic syn-
drome being the second most common manifestation of
renal disease in this patient group [14, 22]. What seems
to be a problem is the difficulty to define the epidemi-
ology of AKI. This is partly due to the fact that the
clinical picture of AKI is very heterogeneous, which has
been reflected by the existence of various classification
systems based on different diagnostic criteria with the
Fig. 1 Frequency (a) and relative frequency (b) distribution of selected kidney biopsy based diagnoses according to age of disease onset
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most recent one announced by KDIGO in 2012 [23].
Our study covered the period between 2009 and 2014,
the clinical data were provided by different renal centers,
and the descriptions of a disease course were not uni-
form and precise enough to allow for a reliable distinc-
tion between AKI, AKI superimposed on CKD and
‘pure’ CKD.
Although the spectrum of diseases affecting people
aged ≥65 is the same as in younger population, there are
some distinct differences in the frequency of certain
nephropathies between these two age groups. Our obser-
vation of the relatively high incidence of MGN among
elderly individuals is in line with the reports of others
[12, 13, 22, 24, 25]. Our data indicate that the peak
frequency of MGN occurs at the age 55-64 years, and a
peak relative frequency at the age of 65–74 years (Fig. 1).
The histological recognition of MGN provides important
rationale for the use of immunosuppressive therapy,
especially if progressive eGFR lowering is observed.
Focal segmental glomerulosclerosis was recognized as
the second most common histological diagnosis in both
elderly and younger patients (17.3 and 15.3% respect-
ively). As in our study, an association between FSGS and
nephrotic-range proteinuria, as well as no difference in
FSGS frequency between patients aged ≥65 and those
aged <65 were observed by others [13, 16, 17]. In a vast
majority of our cases studied morphological and clinical
features suggested the secondary nature of glomerular
sclerosis, but the etiology of this process was ambiguous.
Although in many elderly patients a contribution of
aging, hypertension and arteriosclerosis to the FSGS
development could not be excluded, the histological
picture was not specific enough to justify a diagnosis of
hypertensive nephropathy or arterionephrosclerosis.
In a few published studies that analyzed the prevalence
of kidney biopsy based diagnoses in elderly individuals
the percentage of cases, in which age and/or hyperten-
sion related lesions were dominant microscopic finding
ranged from 1.6% in Chinese patients to 6.2% in Japa-
nese cohort [19, 24, 26]. The proportion of aforemen-
tioned diagnosis in our elderly group was 1.7% (Table 2),
despite the fact that as much as 84.2% of patients aged
≥65 suffered from hypertension (Table 1.)
Amyloidosis was found to be the third most common
histological diagnosis in our elderly patients with a
prevalence of 13.9% as compared with 3.7% in younger
individuals (P < 0.001). These findings are in line with
the reports of others [13, 17, 20]. Our data show the
peak frequency of amyloidosis at the age of 55–64,
whereas the highest relative frequency of this disease
occurred at the age of 65–74 (Fig. 1). Amyloidosis was
found to be the leading (25.2%) histological finding
among elderly patients with nephrotic range proteinuria
without hematuria (Table 3.). Although a nephrotic-
range proteinuria without hematuria was the most
common presentation of amyloidosis in the elderly
(61.7%), in a substantial percentage of cases (19%) the
disease was manifested by non-nephrotic proteinuria.
The latter finding should be emphasized, since many
nephrologists refrain from kidney biopsy in an elderly
Table 3 Distribution of renal biopsy diagnoses among elderly and younger adult patients with nephrotic range proteinuria
Nephrotic range proteinuria
with hematuria
P Nephrotic range proteinuria
without hematuria
P Nephrotic range proteinuria




18–64 (n = 461) ≥65 (n = 115) 18–64 (n = 453) ≥65 (n = 188) 18–64 (n = 916)
MGN 22 (30.1%) 49 (10.6%) <0.001 25 (21.7%) 106 (23.4%) 0.804 47 (25.0%) 155 (16.9%) 0.013
FSGS 15 (20.6%) 79 (17.1%) 0.508 23 (20.0%) 81 (17.9%) 0.591 38 (20.2%) 160 (17.5%) 0.404































IgAN 6 (8.2%) 114 (24.7%) 0.001 4 (3.5%) 39 (8.6%) 0.075 10 (5.3%) 154 (16.8%) <0.001
MCD 5 (6.9%) 30 (6.5%) 0.804 11 (9.6%) 84 (18.5%) 0.025 16 (8.5%) 114 (12.5%) 0.137
Membrano-proliferative GN 5 (6.9%) 30 (6.5%) 0.804 1 (0.9%) 11 (2.4%) 0.475 6 (3.2%) 41 (4.5%) 0.553
DKD 2 (2.7%) 26 (5.6%) 0.405 13 (11.3%) 23 (5.1%) 0.029 15 (8.0%) 49 (5.4%) 0.170
LN 1 (1.4%) 51 (11.1%) 0.005 0 23 (5.1%) 0.007 1 (0.5%) 74 (8.1%) <0.001
End-stage kidney 1 (1.4%) 4 (0.9%) 0.522 1 (0.9%) 8 (1.8%) 0.695 2 (1.1%) 12 (1.3%) 1.000
Arterionephrosclerosis 1 (1.4%) 2 (0.4%) 0.357 1 (0.9%) 5 (1.1%) 1.000 2 (1.1%) 7 (0.8%) 0.655
MGA 0 3 (0.7%) 1.000 1 (0.9%) 11 (2.4%) 0.475 1 (0.5%) 15 (1.6%) 0.498
Thrombotic microangiopathy 0 9 (2.0%) 0.618 1 (0.9%) 6 (1.3%) 1.000 1 (0.5%) 15 (1.6%) 0.498
Unclassified lesions 0 13 (2.8%) 0.232 3 (2.6%) 14 (3.1%) 1.000 3 (1.6%) 27 (3.0%) 0.458
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patient with mild proteinuria, in whom concomitant
amyloidosis-related cardiomyopathy can be easily misin-
terpreted as an ischemic heart disease.
Several authors reported the proportion of diabetic
kidney disease ranging between 2.2% up to 10% in renal
biopsy registries [19, 24]. The results of ours implicate
that in people aged ≥65 DKD constitutes 4.6% of all
renal-biopsy diagnoses. In our cohort the peak frequency
and the highest relative frequency of this disease
occurred at the age of 55–64 years (Fig. 1). The usual in-
dications for renal biopsy in diabetic patients include: an
abrupt onset or rapid progression of kidney disease, the
presence of active urinary sediment, and the progression
of proteinuria in the absence of diabetic retinopathy or
neuropathy. Since the group of diabetic patients in our
cohort is not representative for the whole population of
diabetics, it should be noted that 75% of our elderly dia-
betic patients had non-diabetic kidney disease upon kid-
ney biopsy, which is in line with the observation made
by Sharma et al. [27]. These results may be partially ex-
plained by the relatively short duration of diabetes at the
time of kidney biopsy in our patients (median 7.16 years
for diabetic patients studied, range 0–24 years), as well
as by the fact that in 40% of biopsies from diabetic indi-
viduals electron microscopy was not performed, which
does not allow for the exclusion of early phase of DKD.
One of the leading histological diagnoses in general,
and the most common renal disease manifested by non-








Coincidence of diabetic kidney disease
and other nephropathy
P
≥ 65 (n = 64) 48 (75.0%) 11 (17.0%) 4 (6.0%)a 0.612
18–64 (n = 160) 98 (61.3%) 52 (32.5%) 10 (6.3%)b
a2 cases of MGN, 1case of MCD and 1 case of IgAN
b6 cases of IgA-N, 1 case of LCDD, 1case of MCD, 2 cases of MGN












18–64 (n = 787) ≥65
(n = 58)
18–64 (n = 328) ≥65
(n = 134)































IgAN 15 (19.7%) 336 (42.7%) <0.001 5 (8.6%) 74 (22.6%) 0.013 20 (14.9%) 413 (36.7%) <0.001
FSGS 11 (14.5%) 97 (12.3%) 0.586 12 (20.7%) 65 (19.8%) 0.860 23 (17.2%) 163 (14.5%) 0.439
Unclassified lesions 7 (9.2%) 29 (3.7%) 0.032 3 (5.2%) 24 (7.3%) 0.781 10 (7.5%) 53 (4.7%) 0.204
MGN 4 (5.3%) 27 (3.4%) 0.342 10 (17.2%) 40 (12.2%) 0.292 14 (10.5%) 67 (6.0%) 0.046
LN 2 (2.6%) 73 (9.3%) 0.049 2 (3.5%) 28 (8.5%) 0.285 4 (3.0%) 102 (9.1%) 0.013
Tubulointerstitial nephritis 2 (2.6%) 4 (0.5%) 0.091 4 (6.9%) 10 (3.1%) 0.242 6 (4.5%) 16 (1.4%) 0.023
LCDD/HCDD 2 (2.6%) 2 (0.3%) 0.041 1 (1.7%) 1 (0.3%) 0.278 3 (2.2%) 3 (0.3%) 0.019
Membrano-proliferative GN 2 (2.6%) 15 (1.9%) 0.656 0 9 (2.7%) 0.366 2 (1.5%) 24 (2.1%) 1.000
End-stage kidney 2 (2.6%) 18 (2.3%) 0.694 2 (3.5%) 7 (2.1%) 0.630 4 (3%) 25 (2.2%) 0.540
TBMD 1 (1.3%) 23 (2.9%) 0.715 0 2 (0.6%) 1.000 1 (0.8%) 25 (2.2%) 0.513
MCD 1 (1.3%) 5 (0.6%) 0.426 4 (6.9%) 8 (2.4%) 0.089 5 (3.7%) 13 (1.2%) 0.035
Amyloidosis 1 (1.3%) 7 (0.9%) 0.523 8 (13.8%) 15 (4.6%) 0.013 9 (6.7%) 23 (2.1%) 0.005
MGA 0 31 (3.9%) 0.102 1 (1.7%) 16 (4.9%) 0.281 1 (0.8%) 48 (4.3%) 0.046
DKD 0 8 (1.0%) 1.000 1 (1.7%) 5 (1.5%) 1.000 1 (0.8%) 13 (1.2%) 1.000
Thrombotic microangiopathy 0 10 (1.3%) 1.000 1 (1.7%) 9 (2.7%) 1.000 1 (0.8%) 20 (1.8%) 0.718
Arterionephrosclerosis 0 2 (0.3%) 1.000 2 (3.5%) 6 (1.8%) 0.344 2 (1.5%) 8 (0.7%) 0.289
Normal kidney morphology 0 12 (1.5%) 0.614 0 2 (0.6%) 1.000 0 14 (1.3%) 0.385
Alport syndrome 0 8 (1.0%) 1.000 0 2 (0.6%) 1.000 0 10 (0.9%) 1.000
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nephrotic range proteinuria with hematuria in our
elderly patients was pauci-immune GN. Notably, 23.8%
of elderly and 24.8% of younger patients with pauci-im-
mune GN suffered from nephrotic-range proteinuria.
Pauci-immune GN being one of the leading diagnoses
made upon kidney biopsy among elderly individuals was
reported by others [13, 25, 28, 29]. The peak frequency
and the highest relative frequency of this disease in our
patients studied occurred at the age of 55-64 years
(Fig. 1). In a vast majority of cases pauci immune GN is
associated with the presence of ANCA vasculitis, with
peak incidence of 52.9 per million being observed
among people aged 65–74 [30]. It is worth mentioning
that in contrast to younger individuals, in the elderly
vasculitis more commonly manifests with renal disease,
and less frequently involves upper respiratory tract [29].
Vasculitis-related symptoms such as myalgia and head-
ache may be easily misdiagnosed as common afflictions
of the elderly, e.g., polymyalgia rheumatica [31].
Conclusions
Our analysis confirmed differences in the prevalence of
certain kidney diseases between elderly and younger
individuals. Elderly patients were more frequently neph-
rotic, hypertensive and diabetic, and have lower eGFR at
the time of the biopsy than younger individuals. A lead-
ing clinical manifestation in patients aged ≥65 years
submitted to kidney biopsy was proteinuria, most com-
monly of nephrotic range, which in majority of cases
was related to glomerulopathies, Hypertension and age-
related lesions rarely were found an exclusive or domin-
ant finding in a kidney biopsy or a cause of proteinuria
in individuals aged ≥65 years. The relatively high preva-
lence of potentially curative kidney diseases in the eld-
erly individuals implicates the importance of renal
biopsy in these patients.
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